SEC Filing Summary: ChromaDex Corp. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corp. on September 20, 2012. The report discloses non-financial material information regarding clinical test results for the company's product, pterostilbene, which were announced at the American Heart Association meeting on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report focused on regulatory disclosure of scientific data rather than financial performance.
Material Changes
The material event reported is the release of test results concerning the impact of pterostilbene on blood pressure and other metabolic parameters in adults. No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the issuance of a press release and the attachment of an abstract detailing the clinical study results. The filing explicitly states that the information provided, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements unless expressly set forth.
Key Facts for Investor Verification
- Verify the full text of the attached abstract (Exhibit 99.1) regarding pterostilbene's impact on blood pressure.
- Review the press release (Exhibit 99.2) for specific details on the study methodology and outcomes.
- Confirm that this filing does not constitute a formal financial update or forward-looking guidance on earnings.
- Note that the registrant is ChromaDex Corp., not Niagen Bioscience, Inc., as indicated in the metadata request.